JCAR014

JCAR014 is an investigational chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of various B-cell malignancies. It uses autologous (patient-derived) T cells that are genetically engineered to express a CAR targeting the B-cell surface antigen CD19. The construct includes a 4-1BB co-stimulatory domain to enhance persistence and activity. The product is notable for its defined composition of helper (CD4+) and cytotoxic (CD8+) CAR-T cells in a fixed ratio to optimize efficacy while reducing toxicity compared to other CAR-T therapies[1][3][7]. Mechanistically, these modified T-cells recognize and kill malignant B-cells expressing CD19 through immunologic cytotoxicity. Primary indications under investigation include non-Hodgkin’s lymphoma (including diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), small lymphocytic lymphoma, precursor cell lymphoblastic leukaemia-lymphoma, indolent NHL, relapsed acute lymphoblastic lymphoma, primary mediastinal large b-cell lymphoma[3][6][7][8]. The drug was originally developed by Fred Hutchinson Cancer Research Center with further development by Juno Therapeutics; Bristol Myers Squibb now leads clinical development following acquisition.

Other names

CD19CAR-CD28-zeta-EGFRt T-lymphocytesCD-19CAR-CD28-zeta-EGFRt T-lymphocytesCD 19CAR-CD28-zeta-EGFRt T-lymphocytesCD19 CAR-T cellsCD-19 CAR-T cellsCD 19 CAR-T cellsJCAR-014JCAR014JCAR 014